Relmada Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Relmada Therapeutics (Nasdaq: RLMD), a clinical-stage biotechnology company focused on oncology and central nervous system disorders, announced that senior management will participate in one-on-one meetings at the Wells Fargo 21st Annual Healthcare Conference in Boston, MA, from September 8–10, 2026.
Investors can request 1×1 meetings through their Wells Fargo representative.
Details
News Market Reaction – RLMD
On Sep 1, the day this news came out, RLMD closed 2.29% above the previous close. Argus tracked a peak move of +14.8% during that session. Our momentum scanner recorded 5 alerts in the available session data. Relative volume reached 4.6x the daily average during tracking.
Data tracked by StockTitan Argus for the Sep 1 session.
Key Figures
- Announcement date
- September 1, 2026
- Conference participation announcement
- Conference edition
- 21st annual
- Wells Fargo Healthcare Conference
- Conference dates
- September 8–10, 2026
- Wells Fargo Healthcare Conference
- Meeting format
- 1×1 meetings
- Management meetings at the conference
Historical Context
-
Second-quarter results included a net loss and increased research and development expense.
-
Bipin Dalmia joined as chief business officer to lead strategy and business development.
-
The company scheduled its second-quarter results conference call for August 6, 2026.
-
Relmada joined the Russell 2000 and Russell 3000 indexes after the June 26 market close.
-
Michael Quirk became senior advisor for the sepranolone program.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CORAL GABLES, Fla., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced that senior management will participate in one-on-one meetings at the Wells Fargo 21st Annual Healthcare Conference being held in Boston, MA, from September 8 - 10, 2026.
Wells Fargo 21st Annual Healthcare Conference Details
Format: One-on-one Meetings
Date: September 8 - 10, 2026
If you are interested in arranging a 1×1 meeting with management at the conference, please contact your Wells Fargo representative.
About Relmada Therapeutics, Inc.
Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology and central nervous system conditions. Its lead candidates, NDV-01 and sepranolone, are advancing through clinical development with the potential to address significant unmet needs.
For more information, visit www.relmada.com
Investor Contact:
Brian Ritchie
LifeSci Advisors
britchie@lifesciadvisors.com
Media Inquiries:
Corporate Communications
media@relmada.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.